Corcept Therapeutics Incorporated (CORT)
CORT moved a median of +0.11% 30 minutes after news, and +0.32% by the close. How CORT actually reacts to news — the realized, point-in-time move the market made, measured across 1,158 labeled events over the last three years with zero look-ahead.
CORT’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 50% | 1,147 |
| 30-min | +0.11% | 53% | 1,150 |
| 60-min | +0.07% | 51% | 1,150 |
| to close | +0.32% | 55% | 1,150 |
| Middle 50% of CORT reactions | -0.56% to +1.06% |
|---|---|
| Median reaction (30-min) | +0.11% |
| Measured reactions | 1,158 |
Half of all Corcept Therapeutics Incorporated news events land between -0.56% and +1.06% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How CORT reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 22 | -0.11% | 32% | -0.32% |
| Analyst downgrades | 15 | -0.66% | 33% | -0.77% |
| Rating reiterations | 76 | +0.26% | 57% | +0.20% |
| Price-target raises | 21 | 0.00% | 48% | +0.06% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how CORT ranks against every other measured name →
That’s how CORT usually reacts — get an email when it moves on news →Email me when CORT moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CORT's baseline. Nothing else.
Recent CORT events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Corcept Announces Planned Leadership Transition | Press release | Business Wire | +1.16% | -3.74% | |
| Form 8-K CORCEPT THERAPEUTICS For: Sep 22 | SEC filing · Form 8-K | SEC EDGAR | +1.16% | -3.74% | |
| Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant) | Press release | Business Wire | +0.12% | -5.57% | |
| Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update | Press release | Business Wire | +2.58% | +7.89% | |
| Form 10-Q CORCEPT THERAPEUTICS For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +2.58% | +7.89% | |
| Form 8-K CORCEPT THERAPEUTICS For: Jul 29 | SEC filing · Form 8-K | SEC EDGAR | +2.58% | +7.89% | |
| Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call | Press release | Business Wire | +1.82% | +6.25% | |
| Lifshitz Law PLLC Announces Investigations of Corcept Therapeutics, Inc. (NASDAQ: CORT), Gartner, Inc. (NYSE: IT), REGENXBIO Inc. (NASDAQ: RGNX), and Graphic Packaging Holding Company (NYSE: GPK) | Press release | ACCESS Newswire | +0.96% | +0.19% | |
| Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome | Press release | Business Wire | -0.06% | -3.51% | |
| Form 8-K CORCEPT THERAPEUTICS For: Jun 17 | SEC filing · Form 8-K | SEC EDGAR | -0.06% | -3.51% | |
| Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym® | Press release | Business Wire | +0.97% | +0.62% | |
| Form 8-K CORCEPT THERAPEUTICS For: May 19 | SEC filing · Form 8-K | SEC EDGAR | -0.18% | +2.42% | |
| Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure | Press release | Business Wire | -0.47% | +1.66% | |
| Form S-8 CORCEPT THERAPEUTICS | SEC filing · Form S-8 | SEC EDGAR | -0.47% | +1.66% | |
| Form 8-K CORCEPT THERAPEUTICS For: May 21 | SEC filing · Form 8-K | SEC EDGAR | +0.17% | +1.34% | |
| Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome | Press release | Business Wire | +1.88% | +3.13% | |
| Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis | Press release | Business Wire | -3.56% | +6.06% | |
| Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update | Press release | Business Wire | -3.56% | +6.06% | |
| Form 10-Q CORCEPT THERAPEUTICS For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -3.56% | +6.06% | |
| Form 8-K CORCEPT THERAPEUTICS For: Apr 30 | SEC filing · Form 8-K | SEC EDGAR | -3.56% | +6.06% | |
| Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call | Press release | Business Wire | -2.29% | +0.33% | |
| Corcept to Present New Data from Pivotal Phase 3 ROSELLA Trial of Lifyorli™ (Relacorilant) in Patients with Platinum-Resistant Ovarian Cancer at ASCO 2026 | Press release | Business Wire | -0.82% | +0.49% | |
| Corcept Therapeutics Incorporated Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CORT | Press release | PR Newswire | -0.89% | +1.00% | |
| Form DEF 14A CORCEPT THERAPEUTICS For: Apr 17 | SEC filing · Form DEF | SEC EDGAR | -0.89% | +1.00% | |
| Corcept Therapeutics Incorporated Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CORT | Press release | PR Newswire | +1.07% | +4.21% | |
| Corcept Presents Complete Data from Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet: Lifyorli™ (Relacorilant) Plus Nab-Paclitaxel Improves Overall Survival in Patients with Platinum-Resistant Ovarian Cancer | Press release | Business Wire | +1.07% | +4.21% | |
| Lifshitz Law PLLC Announces Investigations of Corcept Therapeutics, Inc. (NASDAQ: CORT), NuScale Power Corporation (NYSE: SMR), PayPal Holdings, Inc. (NASDAQ: PYPL), and Enphase Energy, Inc. (NASDAQ: ENPH) | Press release | ACCESS Newswire | — | — | |
| Corcept Therapeutics Incorporated Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CORT | Press release | PR Newswire | -1.28% | -3.11% | |
| Corcept Therapeutics Incorporated Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CORT | Press release | PR Newswire | +2.49% | +0.82% | |
| Corcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific Session | Press release | Business Wire | +2.49% | +0.82% | |
| FDA Approves Corcept’s Selective Glucocorticoid Receptor Antagonist Lifyorli™ (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer | Press release | Business Wire | +0.83% | +0.28% | |
| Form 8-K CORCEPT THERAPEUTICS For: Mar 25 | SEC filing · Form 8-K | SEC EDGAR | -0.38% | -1.83% | |
| Shareholders who lost money in shares of Corcept Therapeutics (NASDAQ: CORT) should contact Wolf Haldenstein immediately | Press release | GlobeNewswire | — | — | |
| Shareholders who lost money in shares of Corcept Therapeutics (NASDAQ: CORT) should contact Wolf Haldenstein immediately | Press release | PR Newswire | +0.09% | +1.96% | |
| Corcept Therapeutics Incorporated Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CORT | Press release | PR Newswire | -1.87% | -3.91% | |
| Corcept Therapeutics Incorporated Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CORT | Press release | PR Newswire | +0.31% | -0.56% | |
| Shareholders who lost money in shares of Corcept Therapeutics (NASDAQ: CORT) should contact Wolf Haldenstein immediately | Press release | GlobeNewswire | +0.31% | -0.56% | |
| Corcept Therapeutics Incorporated Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CORT | Press release | PR Newswire | -0.36% | -2.50% | |
| REMINDER: Corcept Therapeutics Incorporated Investors With Significant Losses Must Act By April 21, 2026 | Press release | Business Wire | -0.15% | +0.81% | |
| Corcept Therapeutics Incorporated Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CORT | Press release | PR Newswire | +0.19% | +1.25% | |
| Corcept Therapeutics Incorporated Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CORT | Press release | PR Newswire | -0.63% | -2.58% | |
| Important Notice to Long-Term Shareholders of Corcept Therapeutics, Inc. (NASDAQ: CORT); Kyndryl Holdings (NYSE: KD); Molina Healthcare, Inc. (NYSE: MOH); and Unicycive Therapeutics, Inc. (NASDAQ: UNCY): Grabar Law Office Investigates Claims on Your Behal | Press release | GlobeNewswire | -0.63% | -2.58% | |
| Important Notice to Long-Term Shareholders of Corcept Therapeutics, Inc. (NASDAQ: CORT); Integer Holdings Corp. (NYSE: ITGR); Kyndryl Holdings (NYSE: KD); and Molina Healthcare, Inc. (NYSE: MOH): Grabar Law Office Investigates Claims on Your Behalf | Press release | GlobeNewswire | -0.14% | -0.79% | |
| Corcept Therapeutics Incorporated Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CORT | Press release | PR Newswire | +0.75% | +4.08% | |
| Shareholders who lost money in shares of Corcept Therapeutics (NASDAQ: CORT) should contact Wolf Haldenstein immediately | Press release | GlobeNewswire | -0.41% | +1.03% | |
| Corcept Therapeutics Incorporated Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CORT | Press release | PR Newswire | +0.76% | +1.39% | |
| Lifshitz Law PLLC Announces Investigations of Corcept Therapeutics, Inc. (Nasdaq:CORT), Zynex, Inc. (OTC:ZYXIQ), NuScale Power Corporation (NYSE:SMR), and PayPal Holdings, Inc. (Nasdaq:PYPL) | Press release | ACCESS Newswire | +0.76% | +1.39% | |
| Corcept Therapeutics Incorporated Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – CORT | Press release | Business Wire | -2.36% | -3.80% | |
| Corcept Therapeutics Announces Fourth Quarter and Full-Year 2025 Audited Financial Results, Provides Corporate Update | Press release | Business Wire | -2.36% | -3.80% | |
| Form 10-K CORCEPT THERAPEUTICS For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -2.36% | -3.80% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CORT section they belong to.
Where else CORT is measured.
CORT earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| WRIGHT MEDICAL GROUP NV (WMGI) | 1,168 | -0.07% | 42% |
| Acadia Healthcare Company, Inc. (ACHC) | 1,165 | -0.02% | 49% |
| Medpace Holdings, Inc. (MEDP) | 1,147 | -0.01% | 50% |
| Epizyme, Inc. (EPZM) | 1,145 | +0.04% | 51% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Corcept Therapeutics Incorporated's median reaction calculated?
Every labeled CORT news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 1,158 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 53% of CORT's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does CORT's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.